FEMARA® (letrozole): Initial & Extended Adjuvant Therapy For Breast Cancer

*Distant disease-free survival is a secondary end point of BIG 1-98; the primary end point of the study is disease-free survival. Approval is based on a median 26-month follow-up.¹

FEMARA^® (letrozole) is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

FEMARA^® (letrozole) is also indicated for:

Extended adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.

First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.

Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with anti-estrogens.

Click here for Important Safety Information for FEMARA^®.

References: 1. FEMARA^® (letrozole) [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2010. 2. Gradishar W. Landmark trials in endocrine adjuvant therapy for breast carcinoma. Cancer. 2006;106(5):975-981.